MIST Milestone Pharmaceuticals Inc.

Nasdaq milestonepharma.com


$ 2.06 $ 0.01 (0.24 %)    

Monday, 17-Nov-2025 12:05:23 EST
QQQ $ 610.47 $ 4.39 (0.72 %)
DIA $ 471.54 $ 0.68 (0.14 %)
SPY $ 672.39 $ 2.66 (0.4 %)
TLT $ 89.26 $ 0.18 (0.2 %)
GLD $ 374.72 $ 0.78 (0.21 %)
$ 2
$ 2.05
$ 2.05 x 3,595
$ 2.06 x 600
$ 2.00 - $ 2.08
$ 0.63 - $ 2.75
3,158,742
na
170.34M
$ 1.06
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-12-2025 09-30-2025 10-Q
2 08-12-2025 06-30-2025 10-Q
3 05-14-2025 03-31-2025 10-Q
4 03-13-2025 12-31-2024 10-K
5 11-12-2024 09-30-2024 10-Q
6 08-08-2024 06-30-2024 10-Q
7 05-13-2024 03-31-2024 10-Q
8 03-21-2024 12-31-2023 10-K
9 11-13-2023 09-30-2023 10-Q
10 08-10-2023 06-30-2023 10-Q
11 05-11-2023 03-31-2023 10-Q
12 03-29-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-10-2022 06-30-2022 10-Q
15 05-12-2022 03-31-2022 10-Q
16 03-24-2022 12-31-2021 10-K
17 11-12-2021 09-30-2021 10-Q
18 08-11-2021 06-30-2021 10-Q
19 05-17-2021 03-31-2021 10-Q
20 03-29-2021 12-31-2020 10-K
21 11-13-2020 09-30-2020 10-Q
22 08-12-2020 06-30-2020 10-Q
23 05-14-2020 03-31-2020 10-Q
24 03-06-2020 12-31-2019 10-K
25 11-13-2019 09-30-2019 10-Q
26 08-13-2019 06-30-2019 10-Q
27 06-19-2019 03-31-2019 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 milestone-pharmaceuticals-q3-eps-012-beats-016-estimate

Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimat...

 milestone-pharma-says-new-data-analyses-of-investigational-product-for-psvt-etripamil-nasal-spray-consistently-showed-efficacy-and-favorable-safety-profile-across-multiple-studies-comprising-global-development-program

Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of ...

 wells-fargo-initiates-coverage-on-milestone-pharmaceuticals-with-overweight-rating-announces-price-target-of-4

Wells Fargo analyst Mohit Bansal initiates coverage on Milestone Pharmaceuticals (NASDAQ:MIST) with a Overweight rating and ...

 milestone-pharmaceuticals-q2-eps-020-misses-017-estimate

Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.20) per share which missed the analyst consensus estim...

 why-is-milestone-pharmaceuticals-stock-plunging-on-friday

FDA accepts Milestone's response on Cardamyst nasal spray, sets new PDUFA date; company raises $52.5 million to support pot...

 milestone-pharma-prices-525m-equity-offering-with-warrants-offering-is-expected-to-close-on-or-about-july-14-2025

Milestone® Pharmaceuticals Inc. ("Milestone") (NASDAQ:MIST), a biopharmaceutical company focused on the development and...

 hc-wainwright--co-assumes-milestone-pharmaceuticals-at-buy-announces-price-target-of-5

HC Wainwright & Co. analyst Brandon Folkes assumes Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy rating and announc...

 milestone-pharmaceuticals-q1-eps-031-misses-018-estimate

Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.31) per share which missed the analyst consensus estim...

 hc-wainwright--co-maintains-buy-on-milestone-pharmaceuticals-lowers-price-target-to-10

HC Wainwright & Co. analyst Patrick Trucchio maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and lowers the...

 hc-wainwright--co-reiterates-buy-on-milestone-pharmaceuticals-maintains-25-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Milestone Pharmaceuticals (NASDAQ:MIST) with a Buy and maintains...

 why-is-milestone-pharmaceuticals-stock-plunging-today

Milestone Pharmaceuticals' stock drops over 61% after receiving a Complete Response Letter from the FDA for its CARDAMYST NDA.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION